Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,055 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Therapeutic choice for the chronic myeloid leukemia patients in chronic phase showing late suboptimal response to imatinib].
Matsumura I, Nannya Y, Nagai T, Tanimoto K, Fujikawa K, Kasai M, Inaguma Y, Takeuchi M, Niimi H, Kashiwagi H, Imamura Y, Yagi T, Sakamoto E, Okabe M, Aoki G, Katayama T, Okada M, Adachi Y, Saburi Y, Kizaki M. Matsumura I, et al. Among authors: okada m. Rinsho Ketsueki. 2010 Dec;51(12):1762-8. Rinsho Ketsueki. 2010. PMID: 21258186 Japanese.
Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.
Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kasai M, Fukuda T, Azuma H, Takanashi M, Okamoto S, Tsuchida M, Kawa K, Morishima Y, Kodera Y, Kato S; Japan Cord Blood Bank Network. Atsuta Y, et al. Blood. 2009 Feb 19;113(8):1631-8. doi: 10.1182/blood-2008-03-147041. Epub 2008 Dec 22. Blood. 2009. PMID: 19104080 Free article. Clinical Trial.
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sakamaki H, Ishizawa KI, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N, Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T, Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S, Seriu T, Ohno R. Sakamaki H, et al. Among authors: okada m. Int J Hematol. 2009 Apr;89(3):332-341. doi: 10.1007/s12185-009-0260-2. Epub 2009 Mar 5. Int J Hematol. 2009. PMID: 19263190 Clinical Trial.
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.
Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori H, Naoe T. Tojo A, et al. Among authors: okada m. Int J Hematol. 2009 Jun;89(5):679-88. doi: 10.1007/s12185-009-0327-0. Epub 2009 May 19. Int J Hematol. 2009. PMID: 19449194 Clinical Trial.
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.
Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: okada m. Int J Hematol. 2010 Mar;91(2):276-83. doi: 10.1007/s12185-009-0480-5. Int J Hematol. 2010. PMID: 20054669 Clinical Trial.
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan.
Nagai T, Takeuchi J, Dobashi N, Kanakura Y, Taniguchi S, Ezaki K, Nakaseko C, Hiraoka A, Okada M, Miyazaki Y, Motoji T, Higashihara M, Tsukamoto N, Kiyoi H, Nakao S, Shinagawa K, Ohno R, Naoe T, Ohnishi K, Usui N. Nagai T, et al. Among authors: okada m. Int J Hematol. 2010 Jul;92(1):111-7. doi: 10.1007/s12185-010-0621-x. Epub 2010 Jun 25. Int J Hematol. 2010. PMID: 20577839 Clinical Trial.
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Kobayashi Y, Sakamaki H, Fujisawa S, Ando K, Yamamoto K, Okada M, Ishizawa K, Nagai T, Miyawaki S, Motoji T, Usui N, Iida S, Taniwaki M, Uoshima N, Seriu T, Ohno R. Kobayashi Y, et al. Among authors: okada m. Int J Hematol. 2011 Jun;93(6):745-749. doi: 10.1007/s12185-011-0864-1. Epub 2011 May 20. Int J Hematol. 2011. PMID: 21594763
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T. Usuki K, et al. Among authors: okada m. Int J Hematol. 2012 Apr;95(4):409-19. doi: 10.1007/s12185-012-1026-9. Epub 2012 Feb 23. Int J Hematol. 2012. PMID: 22359103 Clinical Trial.
A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.
Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, Yamamoto K, Miyamura K, Taniwaki M, Okada M, Kawaguchi T, Shibata A, Fujii Y, Ono C, Ohnishi K. Nakaseko C, et al. Among authors: okada m. Int J Hematol. 2015 Feb;101(2):154-64. doi: 10.1007/s12185-014-1722-8. Epub 2014 Dec 25. Int J Hematol. 2015. PMID: 25540064 Clinical Trial.
6,055 results